Evidence map›Paper›PMID 40274286›Full record

Observational studyBMJ global health2025

Prospective observational study to assess the feasibility and safety of appropriate

Prayuth Sudathip, Nardlada Khantikul, Aungkana Saejeng, Stephan Duparc, Penny Grewal Daumerie, Caroline Lynch, Elodie Jambert, Saowanee Viboonsanti, Darin Areechokchai, Jerdsuda Kanjanasuwan and 4 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Health-care provider compliance with a revisedLancet regional health. Americas · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Prayuth SudathipDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand psudathip@gmail.com.ORCID http://orcid.org/0009-0004-1685-2141
Nardlada KhantikulThe Office of Disease Prevention and Control 1 Chiangmai, Division of Vector Borne Diseases, Ministry of Public Health, Nonthaburi, Thailand.
Aungkana SaejengThe Office of Disease Prevention and Control 1 Chiangmai, Division of Vector Borne Diseases, Ministry of Public Health, Nonthaburi, Thailand.
Stephan DuparcMMV Medicines for Malaria Venture, Geneva, Switzerland.
Penny Grewal DaumerieImpactPlus, Geneva, Switzerland.
Caroline LynchIndependent regional advisor, Chaing Mai, Thailand.
Elodie JambertMMV Medicines for Malaria Venture, Geneva, Switzerland.
Saowanee ViboonsantiThe Office of Disease Prevention and Control 1 Chiangmai, Division of Vector Borne Diseases, Ministry of Public Health, Nonthaburi, Thailand.
Darin AreechokchaiDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Jerdsuda KanjanasuwanDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Thannika Thong-ArdDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Panupong KowsuratDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Isabelle Borghini-FuhrerMMV Medicines for Malaria Venture, Geneva, Switzerland.
Chantana PadungtodDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction

methodsThis prospective, observational, multicentre, longitudinal study was conducted between 23 May 2022 and 14 September 2023 during pilot implementation at seven sites in Yala and Mae Hong Son provinces. Eligible patients were ≥16 years old with uncomplicated

resultsOf 316

conclusionPoint-of-care quantitative G6PD testing prior to appropriate tafenoquine or primaquine administration was operationally feasible within the Thailand health system, with no concerning adverse events, supporting implementation of this treatment algorithm in areas of active

Indexed as

AminoquinolinesAntimalarialsGlucosephosphate Dehydrogenase DeficiencyMalaria, VivaxPrimaquineAdolescentAdultFeasibility StudiesFemaleGlucosephosphate DehydrogenaseHumansLongitudinal StudiesMaleMiddle AgedPilot ProjectsPoint-of-Care TestingAminoquinolinesAntimalarialsGlucosephosphate DehydrogenasePrimaquinetafenoquineMalariaOther diagnostic or toolParasitologyPublic Health

Identifiers

PMID40274286
PMCPMC12035454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.